By Katherine Hamilton
Atea Pharmaceuticals is reviewing strategic opportunities after cutting a quarter of its workforce.
The Boston biopharmaceutical company, which develops oral antiviral treatments, said Wednesday it has engaged an independent global investment bank to identify possible opportunities, including partnerships on its Phase 3 program for a treatment of patients with HCV.
It also reduced 25% of its employees during the first quarter in an effort to reduce costs. The reduction is expected to save $15 million through 2027, Atea said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 26, 2025 14:18 ET (18:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。